What's Happening?
MeiraGTx, a genetic medicines biotech company, has reacquired the rights to an eye disease gene therapy, bota-vec, from Johnson & Johnson (J&J) for $25 million upfront. This decision follows a failed Phase
3 trial of the therapy, which is aimed at treating X-linked retinitis pigmentosa, a genetic condition causing early childhood blindness. Despite the trial's failure to improve visual-guided mobility, MeiraGTx believes the data supports regulatory applications due to observed improvements in visual acuity and patient-reported outcomes. The company plans to seek regulatory approval in the U.S. and EU by 2027, with J&J eligible for royalties starting in 2029.
Why It's Important?
The reacquisition of bota-vec by MeiraGTx highlights the biotech's commitment to advancing treatments for X-linked retinitis pigmentosa, a condition with significant unmet medical needs. The therapy's potential approval could provide a new treatment option for patients lacking alternatives, potentially improving their quality of life. This move also positions MeiraGTx to transition into a commercial-stage biotech, expanding its market presence and influence in the gene therapy sector. The outcome of this endeavor could impact the biotech industry by setting a precedent for how companies handle setbacks in clinical trials.
What's Next?
MeiraGTx plans to expedite the regulatory filing process for bota-vec in both the U.S. and EU, aiming for submissions by 2027. The company is also developing another therapy, AAV-hAQP1, for radiation-induced xerostomia, with pivotal results expected in 2027. Successful approvals could lead to two product launches, significantly boosting MeiraGTx's market position. The biotech's strategy will likely involve engaging with patient advocacy groups and experts to bolster support for bota-vec's approval, emphasizing the therapy's potential benefits despite previous trial challenges.
